Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Exercise × Clear all

Phase

Phase NA 25 Phase 2 2 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Motor Activity 8 Breast Neoplasms 6 Neoplasms 4 Recurrence 2 Fatigue 2 Body Weight 2 Weight Loss 1 Warts 1 Vomiting 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Nausea 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Insulin Resistance 1 Head and Neck Neoplasms 1 Dementia 1 Colonic Neoplasms 1 Cognitive Dysfunction 1 Asthenia 1 Anomia 1 Alzheimer Disease 1

Interventions

Prednisone 48 Radiotherapy 45 Docetaxel 45 Leuprolide 41 Goserelin 41 bicalutamide 40 enzalutamide 26 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 26 Androgen Antagonists 23 Flutamide 21 Triptorelin Pamoate 20 apalutamide 18 Gonadotropin-Releasing Hormone 15 Abiraterone Acetate 15 Zoledronic Acid 13 Radiation 12 Magnetic Resonance Spectroscopy 12 gallium 68 PSMA-11 11 abiraterone 11 Prednisolone 9 cabazitaxel 8 Estramustine 8 Dexamethasone 8 Buserelin 8 luprolide acetate gel depot 7 darolutamide 7 Standard of Care 7 Specimen Handling 7 Radiotherapy, Conformal 7 Mitoxantrone 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00658229 2012-10-15

PEPC

Oslo University Hospital

Phase 3 Completed

Motor Activity, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡